School of Biomedical Sciences is pleased to invite you to join the following seminar:

Date: Friday, 16 September, 2022

Time: 4:00 pm – 5:30 pm

Via Zoom:  https://hku.zoom.us/j/93779271281?pwd=Kys1SlJvU3BhVENWOEozeVljdmZ2dz09

Meeting ID: 937 7927 1281

Password: 234635

Speaker: Professor Shawn Chen, Nasrat Muzayyin Professor in Medicine and Technology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore; Director of Research, Clinical Imaging Research Centre

Title: "Albumin binder-based molecular imaging and therapy”

Biography

Prof. Xiaoyuan (Shawn) Chen received his PhD in Chemistry from the University of Idaho (1999). After being a faculty at the University of Southern California, Stanford University and then Senior Investigator/Lab Chief at the National Institutes of Health, he is now Nasrat Muzayyin Professor in Medicine and Technology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore. His current research interests are mainly theranostics (radiotheranostics, nanotheranostics, immunotheranostics, magnetotheranostics, phototheranostics, etc.) that can be clinically translatable. He has published over 900 papers and numerous books (Total citations > 110,000, H index 173 based on Google scholar).

Abstract

Theranostics (thera(py)+(diag)nostics) aims to develop molecular diagnostic tests and targeted therapeutics with the goals of individualizing treatment by targeting therapy to an individual's specific disease subtype and genetic profile. Human serum albumin (HSA) is a heart-shaped protein with 3 homogeneous domains, each with 2 subdomains that own the same structural motifs. HSA contains 2 binding sites, one for carrying and delivering small aromatic molecules in blood circulation, the other for incorporating lipophilic carboxylate derivatives. This talk focuses on using Evans blue, a dye that binds reversibly to albumin, for multimodality imaging of blood pool and lymphatic system, and for modifying various structures (protein, peptide, mRNA, ODN and small molecules) for cancer therapy, some of which have been successfully translated into clinic.

ALL ARE WELCOME

Should you have any enquiries, please feel free to contact Miss Angela Wong at 3917 9216.